Simon Tso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Simon Tso has a total of 289 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Wernham
Department of Dermatology, Walsall Healthcare NHS Trust , Walsall
8 shared publications David de Berker
Department of Dermatology, University Hospitals Bristol NHS Foundation Trust , Bristol
5 shared publications- Dennis Niebel
Department of Dermatology, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany
5 shared publications William Hunt
British Association of Dermatologists Sustainability Subcommittee , London
5 shared publications- Danning Li
Department of Dermatology University Hospitals Coventry and Warwickshire Coventry UK
3 shared publications Eleanor Wood
3 shared publications
Latest Publications
- 8 October 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
The environmental burden of melanoma: a national stage-specific carbon footprint analysis
This research letter presents the first population-level England-based stage-specific estimates of the carbon footprint associated with melanoma care.
- 8 October 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
The environmental burden of melanoma: a national stage-specific carbon footprint analysis
This research letter presents the first population-level England-based stage-specific estimates of the carbon footprint associated with melanoma care.
- 24 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Harmonizing vitiligo outcomes: why global context matters
- 24 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Harmonizing vitiligo outcomes: why global context matters
- 29 July 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (11) , 2173-2175
Formulation and systemic therapy
This case describes a young patient presenting with severe chronic hand eczema despite topical corticosteroid treatment with a preference for nonsystemic treatment. She has a Dermatology Life Quality Index (DLQI) score of 12. She has marked clinical improvement after 8 months of topical delgocitinib treatment, demonstrating the emerging role of topical pan-Janus kinase inhibitors as second-line therapy.
- 29 July 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (11) , 2173-2175
Formulation and systemic therapy
This case describes a young patient presenting with severe chronic hand eczema despite topical corticosteroid treatment with a preference for nonsystemic treatment. She has a Dermatology Life Quality Index (DLQI) score of 12. She has marked clinical improvement after 8 months of topical delgocitinib treatment, demonstrating the emerging role of topical pan-Janus kinase inhibitors as second-line therapy.
- 24 June 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (11) , 2120-2122
A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: early real-world experience in a British cohort
In this UK multicentre study of 54 patients with severe alopecia areata, 15 of 54 (28%) patients taking oral ritlecitinib 50 mg daily achieved a success rate (SALT ≤ 20) at 6 months, demonstrating real-world efficacy and safety profiles comparable with pivotal clinical trials. Notably, success was numerically lower in patients with skin of colour (13% vs. 33% in White patients), a subgroup that presented with significantly higher baseline disease severity and a higher likelihood of past diphenylcyclopropenone or systemic treatment.
- 24 June 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (11) , 2120-2122
A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: early real-world experience in a British cohort
In this UK multicentre study of 54 patients with severe alopecia areata, 15 of 54 (28%) patients taking oral ritlecitinib 50 mg daily achieved a success rate (SALT ≤ 20) at 6 months, demonstrating real-world efficacy and safety profiles comparable with pivotal clinical trials. Notably, success was numerically lower in patients with skin of colour (13% vs. 33% in White patients), a subgroup that presented with significantly higher baseline disease severity and a higher likelihood of past diphenylcyclopropenone or systemic treatment.
- Open Access
- 11 June 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (5) , 100606
Educating current and future healthcare professionals on evidence-based sustainable medicine
- 11 June 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (5) , 100606
Open AccessEducating current and future healthcare professionals on evidence-based sustainable medicine
- 19 March 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (9) , 1707-1708
Carbon footprint analysis of electricity, gas and water consumption before and after an educational intervention at a dermatology centre in the UK
We report UK single-centre carbon footprint data falling under Greenhouse Gas Protocol scope 2 (purchased energy including electricity and gas) plus water consumption on a per-patient encounter basis. We also report the impact of an educational package on utility consumption.
- 19 March 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (9) , 1707-1708
Carbon footprint analysis of electricity, gas and water consumption before and after an educational intervention at a dermatology centre in the UK
We report UK single-centre carbon footprint data falling under Greenhouse Gas Protocol scope 2 (purchased energy including electricity and gas) plus water consumption on a per-patient encounter basis. We also report the impact of an educational package on utility consumption.
- 14 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1153-1155
Conceptual approaches to guideline-relevant carbon footprint evaluation in dermatological treatments
This paper describes three conceptual approaches to compare the carbon footprint of diverse treatments during their use phase with the aim to drive international consensus on finding a fair and equitable way to integrate environmental impact into clinical guideline development.
- 14 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1153-1155
Conceptual approaches to guideline-relevant carbon footprint evaluation in dermatological treatments
This paper describes three conceptual approaches to compare the carbon footprint of diverse treatments during their use phase with the aim to drive international consensus on finding a fair and equitable way to integrate environmental impact into clinical guideline development.
- 13 October 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (2) , 324-325
Chronic hand eczema treated with topical delgocitinib cream
A patient describes their experience of living with chronic hand eczema.
- 13 October 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (2) , 324-325
Chronic hand eczema treated with topical delgocitinib cream
A patient describes their experience of living with chronic hand eczema.
- 8 October 2025
- Published by Elsevier in Dermatologic Clinics
- Vol. 44 (1) , 145-155
Sustainability and Procedural Dermatology
- 8 October 2025
- Published by Elsevier in Dermatologic Clinics
- Vol. 44 (1) , 145-155
Sustainability and Procedural Dermatology